TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors

In recent years, chimeric antigen receptor-modified T cell (CAR T cell) therapy has proven to be a promising approach against cancer. Nonetheless, this approach still faces multiple challenges in eliminating solid tumors, one of which being the immunosuppressive tumor microenvironment (TME). Here, w...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JCI insight Jg. 5; H. 4
Hauptverfasser: Tang, Na, Cheng, Chen, Zhang, Xingying, Qiao, Miaomiao, Li, Na, Mu, Wei, Wei, Xiao-Fei, Han, Weidong, Wang, Haoyi
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States American Society for Clinical Investigation 27.02.2020
Schlagworte:
Antigens
Cancer
Cell therapy
Chimeric antigen receptors
CRISPR
Cytokines
Cytotoxicity
Genes
Immunological memory
Ligands
Lymphocytes
Lymphocytes T
Memory cells
Solid tumors
Transforming growth factor-b
Tumor microenvironment
Tumors
Xenografts
Cancer immunotherapy
Oncology
Therapeutics
ISSN:2379-3708, 2379-3708
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:In recent years, chimeric antigen receptor-modified T cell (CAR T cell) therapy has proven to be a promising approach against cancer. Nonetheless, this approach still faces multiple challenges in eliminating solid tumors, one of which being the immunosuppressive tumor microenvironment (TME). Here, we demonstrated that knocking out the endogenous TGF-β receptor II (TGFBR2) in CAR T cells with CRISPR/Cas9 technology could reduce the induced Treg conversion and prevent the exhaustion of CAR T ce lls. Meanwhile, TGFBR2-edited CAR T cells had better in vivo tumor elimination efficacy, both in cell line-derived xenograft and patient-derived xenograft solid tumor models, whether administered locally or systemically. In addition, the TGFBR2-edited CAR T cells could eliminate contralaterally reinoculated xenografts in mice effectively, with an increased proportion of memory subsets within circulating CAR T cells of central memory and effector memory subsets. In conclusion, we greatly improved the in vitro and in vivo function of CAR T cells in TGF-β-rich tumor environments by knocking out endogenous TGFBR2 and propose a potentially new method to improve the efficacy of CAR T cell therapy for treating solid tumors.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Authorship note: NT and CC contributed equally to this work.
ISSN:2379-3708
2379-3708
DOI:10.1172/jci.insight.133977